Research programme: chronic bronchitis targets - Novartis/Rigel

Drug Profile

Research programme: chronic bronchitis targets - Novartis/Rigel

Latest Information Update: 11 Nov 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis; Rigel Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Bronchitis

Most Recent Events

  • 10 Nov 2005 No development reported - Preclinical for Bronchitis in United Kingdom (unspecified route)
  • 15 Dec 2003 This programme is still in active development
  • 01 Jan 2000 Preclinical development for Bronchitis in Switzerland (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top